Grünenthal GmbH

🇩🇪Germany

Country: 🇩🇪Germany

Ownership: Private

Established: 1946-01-01

Employees: 1K

Market Cap: -

Website: http://www.grunenthal.com

Clinical Trials

Comparison of a Single RTX-GRT7039 and Placebo Intra-articular Injection for Pain Associated With Osteoarthritis of the Knee

Phase 3

Completed

Conditions: Osteoarthritis

Interventions: Drug: Placebo
Drug: RTX-GRT7039

First Posted Date: 2022-07-08

Last Posted Date: 2024-11-14

Lead Sponsor: Grünenthal GmbH

Target Recruit Count: 450

Registration Number: NCT05449132

Locations: 🇺🇸
Chicago Clinical Research Institute Inc., Chicago, Illinois, United States
🇺🇸
Acclaim Clinical Research, Inc., San Diego, California, United States
🇺🇸
Allied Biomedical Research Institute, Miami, Florida, United States

and more 76 locations

Open-label Trial to Check the Safety and Tolerability of RTX-GRT7039 Injections for Pain Associated With Osteoarthritis of the Knee

Phase 3

Active, not recruiting

Conditions: Osteoarthritis

Interventions: Drug: RTX-GRT7039

First Posted Date: 2022-05-17

Last Posted Date: 2024-12-20

Lead Sponsor: Grünenthal GmbH

Target Recruit Count: 930

Registration Number: NCT05377489

Locations: 🇺🇸
Progressive Medical Research, Port Orange, Florida, United States
🇺🇸
Gulfcoast Research Institute, Sarasota, Florida, United States
🇺🇸
Palm Beach Research Center, West Palm Beach, Florida, United States

and more 88 locations

Efficacy and Safety of RTX-GRT7039 in Adult Subjects With Knee Osteoarthritis

Phase 3

Completed

Conditions: Osteoarthritis

Interventions: Drug: RTX-GRT7039
Drug: Placebo

First Posted Date: 2022-02-21

Last Posted Date: 2024-12-20

Lead Sponsor: Grünenthal GmbH

Target Recruit Count: 450

Registration Number: NCT05248386

Locations: 🇵🇱
Makmed Nzoz, Nadarzyn, Mazowieckie, Poland
🇫🇷
Hopital Edouard Herriot, Lyon, France
🇫🇷
CHU Nimes Cedex, Nîmes, France

and more 93 locations

Acceptance of Clarithromycin in a Straw Compared to Syrup in Children With Upper Respiratory Tract Infections

Phase 3

Completed

Conditions: Pharyngitis
Bronchitis
Otitis Media
Tonsillitis

Interventions: Drug: Clarithromycin DST (125 mg)
Drug: Clarithromycin Syrup (125 mg)
Drug: Clarithromycin DST (187.5 mg)
Drug: Clarithromycin Syrup (187.5 mg)
Drug: Clarithromycin DST (250 mg)
Drug: Clarithromycin Syrup (250 mg)

First Posted Date: 2019-07-11

Last Posted Date: 2019-07-11

Lead Sponsor: Grünenthal GmbH

Target Recruit Count: 265

Registration Number: NCT04016051

Locations: 🇩🇪
DE02, München, Germany
🇵🇱
PL06, Kraków, Poland
🇩🇪
DE14, München, Germany

and more 17 locations

Drug-drug Interaction Study to Evaluate the Effect of Omeprazole on CG5503 (Tapentadol)

Phase 1

Completed

Conditions: Pharmacokinetic

Interventions: Drug: Tapentadol IR capsule
Drug: Omeprazole capsule

First Posted Date: 2019-06-10

Last Posted Date: 2019-06-10

Lead Sponsor: Grünenthal GmbH

Target Recruit Count: 32

Registration Number: NCT03979989

Locations: 🇧🇪
J&JPRD Clinical Pharmacology Unit, Merksem, Belgium

Pharmacokinetic Characterization of Two Novel CG5503 Tablet Formulations in Healthy Volunteers

Phase 1

Completed

Conditions: Pharmacokinetics

Interventions: Drug: Tapentadol Test Product 1
Drug: Tapentadol Test Product 2
Drug: Tapentadol Prolonged-release Reference Product

First Posted Date: 2019-05-20

Last Posted Date: 2019-05-20

Lead Sponsor: Grünenthal GmbH

Target Recruit Count: 10

Registration Number: NCT03956134

Locations: 🇩🇪
Department of Clinical Pharmacology, Grünenthal GmbH, Aachen, Germany

Investigation How CG5503 is Taken up and Excreted From the Body After 2 Minutes Intravenous Infusion With and Without Oral Co-administration of Charcoal

Phase 1

Completed

Conditions: Pharmacokinetic

Interventions: Drug: 4 ml CG5503
Drug: 5 g charcoal powder

First Posted Date: 2019-05-16

Last Posted Date: 2019-05-16

Lead Sponsor: Grünenthal GmbH

Target Recruit Count: 14

Registration Number: NCT03951987

Locations: 🇩🇪
Department of Clinical Pharmacology Grünenthal GmbH, Aachen, Germany

Effect of a Multiple-dose Oral Administration of CG5503 PR on the Electrical Activity of the Heart in 48 Healthy Men and Women

Phase 1

Completed

Conditions: Prolonged QTc Interval
Pharmacokinetic

Interventions: Drug: 100 mg CG5503 (tapentadol hydrochloride) PR tablet
Drug: Placebo matching CG5503 PR tablet
Drug: Placebo matching moxifloxacin capsule
Drug: 400 mg Moxifloxacin tablet (overencapsulated)

First Posted Date: 2019-05-15

Last Posted Date: 2019-05-17

Lead Sponsor: Grünenthal GmbH

Target Recruit Count: 48

Registration Number: NCT03951402

Locations: 🇩🇪
DE001 - Contract research organisation, Neuss, Germany

A Study to Investigate Differences in the Extent and Rate of Absorption of Doxylamine/Pyridoxine From 2 Different Products Under Fasting Conditions

Phase 1

Withdrawn

Conditions: Bioavailability

Interventions: Drug: doxylamine succinate 10 mg/pyridoxine hydrochloride 10 mg combination
Drug: Diclegis (Registered Trademark)

First Posted Date: 2019-04-05

Last Posted Date: 2019-07-11

Lead Sponsor: Grünenthal GmbH

Registration Number: NCT03905564

Clinical Pilot Study in Healthy Men to Characterize the Uptake of Buprenorphine Into and Its Elimination From the Body After Topical Application of Two New Forms of a Skin Patch in Comparison to a Reference Patch

Phase 1

Completed

Conditions: Pain

Interventions: Drug: Matching placebo patch to T1
Drug: Matching placebo patch to R
Drug: Matching placebo patch to T2

First Posted Date: 2018-12-24

Last Posted Date: 2018-12-24

Lead Sponsor: Grünenthal GmbH

Target Recruit Count: 47

Registration Number: NCT03785613

Locations: 🇨🇭
Swiss Pharma Contract, Allschwil, Switzerland

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy